Reproducibility of pre-clinical animal research improves with heterogeneity of study samples

Bernhard Voelkl*, Lucile Vogt*, Emily S. Sena, Hanno Würbel

Supporting Text
Figure A: Inclusion/exclusion criteria for the data set of hypothermia studies. The CAMARADES database contains a total of 277 comparisons between a control and a hypothermia treated group. We included only comparisons where the outcome variable was infarct volume (N=223) with a known author for correspondence (N=215), derived from a peer-reviewed article (N=192) and for which an infarct was present (i.e. induction of the lesion was successful. N=190). In order to ensure that comparisons were independent (i.e. they came from different laboratories), we classified comparisons by corresponding author and applied an additional set of inclusion criteria to obtain only one comparison per corresponding author. The 190 comparisons were published by 50 different corresponding authors. When more than one comparison was published by the same author, we selected the comparison with the largest sample size in the treatment group. If more than one study had shared maximum sample size, the study with the largest sample size in the control group was selected. When more than one study had the same sample sizes for both groups, we selected the comparison for which the lowest hypothermia temperature was used. Finally, if there were still more than one comparison by corresponding author, we selected the first comparison on the list.
<table>
<thead>
<tr>
<th>Intervention</th>
<th>Outcome</th>
<th>Species</th>
<th>restrict</th>
<th>N</th>
<th>Power: Median</th>
<th>Quartiles</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>hypothermia</td>
<td></td>
<td></td>
<td></td>
<td>0.95</td>
<td>0.82-0.99</td>
</tr>
<tr>
<td>1</td>
<td>tPA</td>
<td>Rat</td>
<td>Yes</td>
<td>50</td>
<td>0.14</td>
<td>0.12-0.17</td>
</tr>
<tr>
<td>2</td>
<td>Trastuzumab</td>
<td>Mouse</td>
<td>No</td>
<td>58</td>
<td>0.77</td>
<td>0.55-0.87</td>
</tr>
<tr>
<td>3</td>
<td>FK506</td>
<td>Rat</td>
<td>Yes</td>
<td>31</td>
<td>0.95</td>
<td>0.92-0.96</td>
</tr>
<tr>
<td>4</td>
<td>Rosiglitazone 2</td>
<td>Rodent</td>
<td>No</td>
<td>21</td>
<td>0.93</td>
<td>0.83-0.96</td>
</tr>
<tr>
<td>5</td>
<td>IL-1RA</td>
<td>Rodent</td>
<td>No</td>
<td>37</td>
<td>0.42</td>
<td>0.34-0.57</td>
</tr>
<tr>
<td>6</td>
<td>Cardiosphere DC EF (%)</td>
<td>Rodent</td>
<td>Yes</td>
<td>35</td>
<td>0.98</td>
<td>0.97-0.99</td>
</tr>
<tr>
<td>7</td>
<td>Estradiol</td>
<td>Rat</td>
<td>Yes</td>
<td>24</td>
<td>0.57</td>
<td>0.37-0.63</td>
</tr>
<tr>
<td>8</td>
<td>Human MSC</td>
<td>Rat</td>
<td>No</td>
<td>26</td>
<td>0.56</td>
<td>0.56-0.78</td>
</tr>
<tr>
<td>9</td>
<td>MK-801</td>
<td>Infarct volume</td>
<td>Rat</td>
<td>Yes</td>
<td>30</td>
<td>0.80</td>
</tr>
<tr>
<td>10</td>
<td>TMZ</td>
<td>Rodent</td>
<td>No</td>
<td>26</td>
<td>0.96</td>
<td>0.84-0.99</td>
</tr>
<tr>
<td>11</td>
<td>c-kit CSC</td>
<td>Rodent</td>
<td>Yes</td>
<td>20</td>
<td>0.54</td>
<td>0.41-0.68</td>
</tr>
<tr>
<td>12</td>
<td>Rat BMSC</td>
<td>Rat</td>
<td>No</td>
<td>25</td>
<td>0.33</td>
<td>0.24-0.36</td>
</tr>
</tbody>
</table>

**Table A:** Descriptors and selection criteria for 12 additional replicate study pools. We searched the CAMARADES database for all drugs or treatments for which we found more than 25 contrasts for the same outcome measure. Outcome measures that were collective terms for various measures or tests (spec. ‘neuro-behavioural score’, ‘memory’, and ‘learning’) were not considered. Contrasts where one of the following data was missing were excluded: sample size, mean outcome, and standard deviation for control and treatment group. Studies done with non-rodent species were excluded. If the majority of studies were done with a single species, only studies with the predominating species were included (indicated by “Mouse” and “Rat” in the column Species), otherwise all species were included (“Rodent” in column Species). If species were excluded this is indicated in the column ‘restrict’. From all contrasts which stem from the same publication only one was selected following the following selection rules: 1. The contrast with the largest overall sample size was selected. 2. If more than one study had shared maximum sample size, the study with the larger sample size in the treatment group was selected. 3. If more than one study shared the maximum number of subjects in the treatment group, one study was selected randomly using a random number generator. Only treatments where 20 or more contrasts remained, after applying the exclusion criteria, entered into the final study pool. N: final number of studies after application of inclusion/exclusion criteria. For each study power was estimated for two-sided mean difference tests; expected effect size and standard deviation were based on mean values for each intervention, sample sizes as reported in the studies. Median power and interquartile range are given for each intervention. A full list with the CAMARADES identifiers of the included studies is given in the supplementary data set ‘S1_Data.csv’. 
<table>
<thead>
<tr>
<th>Intervention</th>
<th>N</th>
<th>ES</th>
<th>S.E.</th>
<th>z</th>
<th>p</th>
<th>CI_L</th>
<th>CI_U</th>
<th>Q</th>
<th>p(Q)</th>
<th>dev</th>
<th>τ²</th>
<th>I²</th>
<th>H²</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 Hypothermia</td>
<td>50</td>
<td>0.48</td>
<td>0.037</td>
<td>12.99</td>
<td>&lt;0.0001</td>
<td>0.41</td>
<td>0.55</td>
<td>667.5</td>
<td>&lt;0.0001</td>
<td>5.86</td>
<td>0.05</td>
<td>91.4</td>
<td>11.56</td>
</tr>
<tr>
<td>1 tPA</td>
<td>57</td>
<td>0.20</td>
<td>0.050</td>
<td>3.40</td>
<td>&lt;0.0001</td>
<td>0.10</td>
<td>0.29</td>
<td>276.6</td>
<td>&lt;0.0001</td>
<td>54.77</td>
<td>0.10</td>
<td>84.8</td>
<td>6.56</td>
</tr>
<tr>
<td>2 Trastuzumab</td>
<td>58</td>
<td>0.46</td>
<td>0.046</td>
<td>10.05</td>
<td>&lt;0.0001</td>
<td>0.37</td>
<td>0.55</td>
<td>1071.9</td>
<td>&lt;0.0001</td>
<td>46.30</td>
<td>0.09</td>
<td>94.6</td>
<td>18.37</td>
</tr>
<tr>
<td>3 FK 506</td>
<td>31</td>
<td>0.39</td>
<td>0.038</td>
<td>10.31</td>
<td>&lt;0.0001</td>
<td>0.32</td>
<td>0.46</td>
<td>186.5</td>
<td>&lt;0.0001</td>
<td>-8.21</td>
<td>0.03</td>
<td>81.9</td>
<td>5.52</td>
</tr>
<tr>
<td>4 Rosiglitazone 2</td>
<td>21</td>
<td>0.47</td>
<td>0.039</td>
<td>12.20</td>
<td>&lt;0.0001</td>
<td>0.40</td>
<td>0.55</td>
<td>84.4</td>
<td>&lt;0.0001</td>
<td>-12.22</td>
<td>0.02</td>
<td>73.0</td>
<td>3.70</td>
</tr>
<tr>
<td>5 IL-1RA</td>
<td>37</td>
<td>0.34</td>
<td>0.029</td>
<td>11.91</td>
<td>&lt;0.0001</td>
<td>0.29</td>
<td>0.40</td>
<td>114.3</td>
<td>&lt;0.0001</td>
<td>-23.17</td>
<td>0.01</td>
<td>54.5</td>
<td>2.20</td>
</tr>
<tr>
<td>6 Cardiosphere DC</td>
<td>35</td>
<td>-0.52</td>
<td>0.036</td>
<td>-14.50</td>
<td>&lt;0.0001</td>
<td>-0.59</td>
<td>-0.45</td>
<td>248.5</td>
<td>&lt;0.0001</td>
<td>-2.44</td>
<td>0.03</td>
<td>91.9</td>
<td>12.43</td>
</tr>
<tr>
<td>7 Estradiol</td>
<td>24</td>
<td>0.36</td>
<td>0.064</td>
<td>5.61</td>
<td>&lt;0.0001</td>
<td>0.23</td>
<td>0.48</td>
<td>127.4</td>
<td>&lt;0.0001</td>
<td>14.34</td>
<td>0.07</td>
<td>84.7</td>
<td>6.54</td>
</tr>
<tr>
<td>8 Human MSC</td>
<td>26</td>
<td>0.25</td>
<td>0.037</td>
<td>6.56</td>
<td>&lt;0.0001</td>
<td>0.17</td>
<td>0.32</td>
<td>414.4</td>
<td>&lt;0.0001</td>
<td>-9.93</td>
<td>0.03</td>
<td>97.2</td>
<td>35.91</td>
</tr>
<tr>
<td>9 MK 801</td>
<td>30</td>
<td>0.36</td>
<td>0.038</td>
<td>9.41</td>
<td>&lt;0.0001</td>
<td>0.28</td>
<td>0.43</td>
<td>116.5</td>
<td>&lt;0.0001</td>
<td>-6.30</td>
<td>0.03</td>
<td>80.7</td>
<td>5.19</td>
</tr>
<tr>
<td>10 TMZ</td>
<td>26</td>
<td>0.51</td>
<td>0.044</td>
<td>11.72</td>
<td>0.0109</td>
<td>0.43</td>
<td>0.60</td>
<td>176.3</td>
<td>&lt;0.0001</td>
<td>-0.64</td>
<td>0.03</td>
<td>86.1</td>
<td>7.21</td>
</tr>
<tr>
<td>11 c-kit CSC</td>
<td>20</td>
<td>-0.30</td>
<td>0.028</td>
<td>-10.79</td>
<td>&lt;0.0001</td>
<td>-0.36</td>
<td>-0.25</td>
<td>36.7</td>
<td>0.0078</td>
<td>-15.89</td>
<td>0.01</td>
<td>41.7</td>
<td>1.71</td>
</tr>
<tr>
<td>12 Rat BMSC</td>
<td>25</td>
<td>0.19</td>
<td>0.048</td>
<td>3.94</td>
<td>&lt;0.0001</td>
<td>0.10</td>
<td>0.29</td>
<td>955.9</td>
<td>&lt;0.0001</td>
<td>-3.34</td>
<td>0.05</td>
<td>94.6</td>
<td>18.41</td>
</tr>
</tbody>
</table>

Table B: Results of random effects meta-analyses with REML estimators using the R-package *metafor* 1.9-9. N: number of studies in the final study pool, ES: effect size estimate, S.E.: standard error of the effect size estimate, Q: Q-statistic for homogeneity of effect sizes, τ²: between-study variance, dev: deviance, I²: fraction of total heterogeneity divided by total variability, H²: fraction of total variability divided by sampling variability. Meta-analyses were performed after scaling.
Supporting Text:

For estimating the true effect for a treatment we employed fixed effect meta-analyses. Here we will briefly discuss the reasoning of this choice. Historically, clinical multi-centre studies have been analysed in different ways: by simply pooling the data from different centres or by treating centre as a fixed or random variable. Pooling the data from different laboratories and performing a t-test or F-test on the pooled data is a problematic approach, because it clearly violates the assumption of independence of the data. This problem has been discussed at length [S1-S3] and the pitfalls of pseudo-replication by ignoring statistical dependencies are extensively treated in almost all textbooks on experimental design and statistics. We do not recommend this approach, yet we have to note that comparing the diagnostic odds ratios for pooled t-tests, 2-way ANOVAs and mixed-effect models, we see—for the 13 interventions analysed in this study—only marginal differences in the performance of the test methods (Fig. D). Having agreed on accounting for statistical dependencies, which arise from testing multiple animals in the same laboratory, we face the decision whether to treat lab-membership as a fixed or random factor. With respect to this question there seems to be no overall agreement [S4-S6]. We would argue that, conceptually, laboratory is clearly a random factor, as the laboratories, which participated in the multi-lab study, are a random sample from the set of all existing—or potentially existing—laboratories. Arguably, it is not a true random sample (amongst other reasons, national laws and regulations and regional research cultures create spatial correlations), but this might be an issue that cannot be resolved. More importantly, we have to note that this random factor will only have a very limited number of levels—from 2 to 4 in our simulations and perhaps, under rare conditions, up to 5 or 6 for large multi-lab studies. For practical and organizational reasons multi-lab studies in pre-clinical research with even higher numbers of participating laboratories seem rather unrealistic and we are not aware of any attempts at achieving that. With only a few levels of the random factor, the estimation of the hyper-parameters might be rather poor [S7]. Several authors suggested rules-of-thumb for a minimum number of levels for treating a factor as random. These rules-of-thumb typically suggest between 5 and 15 levels as a minimum. This is clearly more than the number of laboratories in a multi-lab study and, following this line of reasoning, one should better treat the factor ‘laboratory’ as a fixed factor. On the other side, Gelman and Hill [S7] have argued that, even in the extreme case of only two levels, the mixed-effect model does not perform worse than a fixed effect model and, therefore, it might even be appropriate in cases, where there are only very few levels of the random variable. Apart from this issue, there is the question how many degrees of freedom one should attribute to the random factor. While some authors suggest that this number can at least be approximated [S8-S10], others disagree and recommend forgoing the reporting of p-values and inferential hypothesis testing [S11]. The question of degrees of freedom is relevant because the estimation of the ratio $p_{sa}$ requires repeated hypothesis testing. Therefore, we didn’t want to dismiss this potential problem light-heartedly. However, we must again note that for the examined range of sample sizes and number of participating laboratories, inference based on random effect models leads to very similar results as inference based on fixed effect models (Fig. D), suggesting that both approaches can be equally feasible.
Supporting References:


Figure B. (a) False positive rate and (b) diagnostic odds ratio (DOR) based on $10^5$ simulated samples based on 50 studies on hypothermia treatment of stroke for overall sample sizes of N=12 (blue), N=24 (orange) and N=48 (grey) animal subjects and k=1 to 4 participating laboratories. Inference was based on fixed effects 2-way ANOVA (Y= Treatment + Lab). The thin red line in panel (a) indicates the 0.05 probability threshold. The diagnostic odds ratio is the ratio of the positive likelihood ratio and the negative likelihood ratio, i.e. DOR= (true positive rate / false positive rate) / (false negative rate / true negative rate).
Figure C. False negative rate (a), false positive rate (b) and diagnostic odds ratio (c) for the 12 replicate data sets (from left to right: row 1: D1-D6, row 2: D7-D12), based on 10^5 simulations for overall sample sizes of N=12 (blue), N=24 (orange) and N=48 (grey) animal subjects.
Figure D. False negative rate and diagnostic odds ratio for the 12 replicate data sets (D1-D12) with $10^3$ simulations per data set. Inference based on: inclusion of zero by the parametric 95% confidence interval (yellow), t-test on pooled data (green), ANOVA with main effects treatment and laboratory only (red), ANOVA with main effects and interaction term (violet), general linear mixed model $Y \sim \text{treatment} + (1 | \text{lab})$ with lab as random effect (blue). In almost all cases diagnostics based on all 5 inference techniques showed very similar behaviour, showing that the findings are not specific to the method of statistical analysis.
Figure D cont.
Pseudocode for simulating multi-lab studies

\[ k = \text{number of laboratories} \]
\[ n = \text{total number of animals} \]

**REPEAT** the following 100,000 times:

- create a list of \( k \) laboratories by sampling without replacement from the study pool
- **FOR** each laboratory
  - *control* = sample \( n/(2k) \) values from a normal distribution with mean and standard deviation as reported for the control group and divide those values by the reported mean value for the control group
  - *treatment* = sample \( n/(2k) \) values from a normal distribution with mean and standard deviation as reported for the treatment group and divide those values by the reported mean value for the control group
- **ENDFOR**
- perform a two-way fixed effect ANOVA on the simulated data
- pool the control values of all laboratories
- pool the treatment values of all laboratories
- calculate the means difference and 95% confidence interval for the pooled data
- test whether confidence interval includes the estimate for the means difference of the meta-analysis

**ENDREPEAT**
Mathematica Code for simulating multi-lab studies
(Effect size estimate, CI95, and 2-way ANOVA)

```
getOneES[labslist_] := Module[
  {nplc, controls, treatments, se, meansdiff, lower, upper, ci, anovap},
  nplc = totalsamplesize/(k*2);   (* k is the number of labs and  *)
  (* nplc is the number of animals per lab per condition  *)
  controls = Flatten[Table[RandomReal[NormalDistribution][data[[labslist[[i]], 4]]],
                            data[[labslist[[i]], 11]], nplc]/data[[labslist[[i]], 4]], {i, k}];
  treatments = Flatten[Table[RandomReal[NormalDistribution][data[[labslist[[i]], 7]]],
                             data[[labslist[[i]], 12]], nplc]/data[[labslist[[i]], 4]], {i, k}];
  (* this generates values sampled from normal distributions  *)
  (* with parameters as reported in the original studies  *)
  se = Sqrt[StandardDeviation[treatments]^2 + StandardDeviation[controls]^2]/totalsamplesize/2];
  (* se is the standard error for the mean difference  *)
  meansdiff = Mean[controls - treatments]; (* this is the mean difference  *)
  anovap =    (* the p-value of a fixed effect ANOVA   *)
    If[k == 1,
      ANOVA[Transpose[{Join[Table[0, { totalsamplesize/2}], Table[1, { totalsamplesize/2}]]},
                       Join[controls, treatments]]][[1, 2, 1, 1, 5]],
      (* for the one-lab condition a one-way ANOVA is made  *)
      (* and the p-value is assigned to the variable anovap  *)
      ANOVA[Transpose[{Join[Table[0, { totalsamplesize/2}], Table[1, { totalsamplesize/2}]]},
                       Flatten[Join[Table[Table[i, {nplc}], {i, k}], Table[Table[i, {nplc}], {i, k}]]],
                       Join[controls, treatments]]][[1, 2, 1, 1, 5]]
                      (* for more than one lab a two-way ANOVA is made  *)
                      (* and the p-value is assigned to the variable anovap  *)
    ];
  lower = meansdiff - zvalue*se; (* this gives the lower 95% CI   *)
  upper = meansdiff + zvalue*se; (* this gives the upper 95% CI   *)
  {truees >= lower && truees <= upper, lower > 0 || upper < 0, anovap, anovap < 0.05}
  (* this gives a list with: the first entry giving True if the true effect size lies within the 95%  *)
  (* confidence interval, and False otherwise, the second entry gives True if the 95% confidence  *)
  (* interval is not including zero and False otherwise, the third entry is the p-value estimate   *)
  (* from the ANOVA, and the fourth entry is True if the p-value of the ANOVA is less than 0.05  *)
  (* and False otherwise  *)
]

results = Table[getOneES[RandomSample[Range[numberofstudies], k]], {100 000}];
(*this repeats the simulation 100.000 times. The number of labs (k) and the true effect size (truees)  *)
(* and the number of studies in the data matrix (numberofstudies) must be specified before executing  *)
(* the function. The data of the original studies must be provided as matrix with the observed mean  *)
(* of the control group in column 4, the mean of the treatment group in column 7, the standard  *)
(* deviation of the control group in column 11 and the standard deviation for the treatment group in  *)
(* column 12.  *)
```
library("metafor")

data<-read.table("dataset_meta.csv", header=TRUE, sep=';')
ncontrol<-data$Number.in.Control.Group
ntreatment<-data$Number.in.Treatment.Group
mtreatment<-data$Reported.Mean.in.Treatment.Group/data$Reported.Mean.in.Control.Group
sdtreatment<-data$Calculated.SD.in.Treatment.Group/data$Reported.Mean.in.Control.Group

# This block reads in observed values from data for reported sample size of the control
group (ncontrol), reported mean of the control group (mcontrol), reported standard deviation
# for the control group (sdcontrol), reported sample size of the treatment group (ntreatment),
# reported mean of the treatment group (mtreatment), and reported standard deviation for
# the treatment group (sdtreatment).

result.meta < rma(m1=mcontrol, m2=mtreatment,
  sd1=sdcontrol, sd2=sdtreatment, n1=ncontrol, n2=ntreatment,
  method="REML", measure="MD")  # "MD" indicates means difference

summary(result.meta)